EPCR knockout: inflaming the discussion
Open Access
- 18 June 2020
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 135 (25) , 2201-2202
Abstract
In this issue of Blood, Magisetty et al provide some surprising results from their studies of the role of endothelial protein C receptor (EPCR) in hemophilic arthropathy. There is a rationale for studying EPCR in hemophilia. It is well recognized that EPCR promotes the activation of protein C (PC) to activated PC (aPC) on endothelial surfaces. The aPC has antithrombotic effects by inactivating factor Va (FVa) on nearby endothelial surfaces. Like aPC, activated coagulation FVIIa can also bind to EPCR. Pavani et al showed that binding to EPCR enhances the hemostatic effect of FVIIa in a mouse hemophilia model, when assayed as ferric chloride–induced thrombosis. The Rao group showed that hemostatic levels of FVIIa displace PC from EPCR, and blockade of EPCR reduces the level of FVIIa needed for hemostasis in a saphenous vein bleeding assay. However, they reported that EPCR blockade by itself did not reduce the severity of bleeding in hemophilic mice. They concluded that downregulation of aPC generation is the major mechanism by which FVIIa interaction with EPCR contributes to the hemostatic effect of FVIIa in hemophilia.Keywords
This publication has 9 references indexed in Scilit:
- EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia miceBlood, 2020
- A Translational Study of TNF-Alpha Antagonists as an Adjunctive Therapy for Preventing Hemophilic ArthropathyJournal of Clinical Medicine, 2019
- Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its actionBlood Advances, 2017
- IL-1β, in contrast to TNFα, is pivotal in blood-induced cartilage damage and is a potential target for therapyBlood, 2015
- The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivoBlood, 2014
- Factor VIIa binding to endothelial cell protein C receptor protects vascular barrier integrity in vivoJournal of Thrombosis and Haemostasis, 2014
- IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophiliaJournal of Thrombosis and Haemostasis, 2013
- Wound healing in haemophilia – breaking the vicious cycleHaemophilia, 2010
- The Protein C PathwayChest, 2003